From Bradykinin B2 Receptor Antagonists to Orally Active and Selective Bradykinin B1 Receptor Antagonists
Martine Barth, Michel Bondoux, Jean‐Michel Luccarini et al. · Journal of Medicinal Chemistry · 2012
The bradykinin (BK) B1 receptor is an attractive target for the treatment of chronic pain and inflammation. Starting from a dual B1 and B2 antagonist, novel antagonists were designed that display low-nanomolar affinity for human B1 receptor and selectivity over B2. Initially, potent imidazoline derivatives were studied, but these compounds suffered from low bioavailability. This issue could be overcome by the use of less basic amino derivatives leading to orally active compounds.
Cited by 14 works. doi:10.1021/jm2016057
Authors
- Martine Barth
- Michel Bondoux
- Jean‐Michel Luccarini
- V. Peyrou
- Pierre Dodey
- Didier Pruneau
- Christine Massardier
- Jean‐Luc Paquet
References
- A Rapid and Sensitive Method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye Binding
- Pharmacology of bradykinin and related kinins.
- Bioregulation of kinins: kallikreins, kininogens, and kininases.
- Bradykinin receptors: Pharmacological properties and biological roles
- The B1 Receptors for Kinins
- Kinin receptors in pain and inflammation
- Evidence for participation of B1 and B2 kinin receptors in formalin‐induced nociceptive response in the mouse
- Hypoalgesia and altered inflammatory responses in mice lacking kinin B1 receptors
- Antinociceptive activity of the bradykinin B1 and B2 receptor antagonists, des-Arg9, [Leu8]-BK and HOE 140, in two models of persistent hyperalgesia in the rat
- Spinal and Supraspinal Mechanisms of Neuropathic Pain